Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those companies that have failed to keep pace, provided they display solid upside potential.
Let's consider two such stocks: (NASDAQ: MRNA) and DexCom (NASDAQ: DXCM). These two healthcare companies have lagged the broader market over the trailing-12-month period, but they stand a good chance of delivering outsized returns well beyond the current bull run.
Moderna is one of the captains of a sinking ship. As a leader in the COVID-19 vaccine market, the biotech is seeing its sales decline rapidly as the need for vaccines subsides. In the first quarter, the company's sales came in at $167 million -- much lower than the $1.9 billion reported during the year-ago period. On the bottom line, Moderna went from net earnings of $0.19 per share in the year-ago quarter to a net loss of $3.07 in the latest quarter.
Source Fool.com
Moderna Inc. Aktie
Einige Buy-Einschätzungen geben Moderna Inc. den Vorteil gegenüber Sell-Einschätzungen.
Ein unerwartetes negatives Potenzial von -2.6% für Moderna Inc., trotz eines niedrigeren Kursziels von 150 € als der aktuelle Kurs von 154.0 €.
